Clinical Trial Update: The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating RC48 plus QL1706 for second-line treatment of HER2-expressing recurrent cervical cancer; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• QL1706
• RC48 (disitamab vedotin)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Recurrent Cervical Cancer | Phase 2 | Status: NOT_YET_RECRUITING